Therapeutic Protease and Peptidase Inhibitors
A special issue of Drugs and Drug Candidates (ISSN 2813-2998). This special issue belongs to the section "Biologics".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 460
Special Issue Editor
Interests: ligands of G protein coupled receptors; receptors for peptide hormones (including bradykinin, anaphylatoxin C5a, neurokinins...); in vitro and in vivo pharmacology (not in silico docking); quantitative assessment of drug antagonism; peptides and peptidomimetics developed as drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The human genome encodes 600–700 proteases (2–3% of genes), defined as hydrolytic enzymes that break down proteins. Digestive proteases were initially characterized, but it was soon understood that proteases mediate many physiological functions in both intra- and extracellular compartments. Protein turnover, autophagy, hormonal maturation and degradation, tissue homeostasis, blood coagulation, cell proliferation, and viral infections are a few examples illustrating the importance of proteases. Peptidases, which hydrolyze smaller substrates such as peptide hormones, are also of prime physiological importance. Proteases and peptidases belong to diverse families according to their catalytic mechanisms (serine proteases, metalloproteinases/peptidases, cysteine, and aspartic proteases).
Therapeutic inhibitors of proteases and peptidases have increasing importance as drugs, either in the form of small molecules (e.g., angiotensin-converting enzyme inhibitors) or proteins of high specificity. Biologic protease inhibitors exploited in therapeutics include replacement therapy of a deficient or dysfunctional protein (e.g., C1 esterase inhibitor) and engineered inhibitory proteins such as monoclonal antibodies, darpins, and Kunitz domain derivatives. Drugs and Drug Candidates invites submissions for this Special Issue titled "Therapeutic Protease and Peptidase Inhibitors".
Dr. François Marceau
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Drugs and Drug Candidates is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- protease inhibitors
- peptidase inhibitors
- small molecule protease inhibitors
- engineered protein inhibitors
- proteases
- peptidases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
